Drug Target Activation Mapping for Personalized Cancer Therapy: Clinical Proteomic Applications to Primary and Metastatic Disease

摘要

The underpinning promise of personalized therapy is that the molecular fingerprint of a patients' tumor becomes the rationale for targeted and patient-tailored therapy. The emphasis on the characterization of this fingerprint has been a genomics-centered analysis with both targeted exome panels, whole genome sequencing, and RNA sequencing comprising the bulk of the molecular detail that most scientists and treating oncologists consider when hearing about personalized or "precision medicine". Stratification and selection of patients for these targeted therapies based on genomic-based assays has certainly been successful in a number of instances such as EGFR mutations, ALK translocations, HER2 amplifications, BRAF mutations, etc., but these approaches have imperfect sensitivity and specificity and often show little to no predictive value (PTEN for mTOR example).